LGHT - ETF AI Analysis
Top Page
Langar Global HealthTech ETF (LGHT)
Rating:69Neutral
Price Target:―
Positive Factors
Recent Short-Term Rebound
The ETF has shown a recent uptick over the past month, suggesting some recovery momentum after earlier weakness.
Focused Health Care Exposure
The fund is heavily invested in health care and health technology companies, giving investors targeted access to this specialized growth area.
Standout Strong Performer in Top Holdings
One of the major positions has delivered very strong gains this year, helping to offset some of the weakness in other holdings.
Negative Factors
Weak Year-to-Date Performance
The ETF’s overall performance so far this year has been negative, which may concern investors looking for more stable returns.
Concentration in a Single Sector
With most assets in health care, the fund is vulnerable if this sector faces regulatory changes, reimbursement pressure, or other industry-specific setbacks.
High Expense Ratio
The ETF charges a relatively high annual fee, which can eat into long-term returns compared with lower-cost alternatives.
LGHT vs. SPDR S&P 500 ETF (SPY)
AUM2.10M
RegionGlobal
Expense Ratio0.85%
Beta0.93
IssuerLangar
Inception DateJan 10, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,309
30 Day Avg. Volume2,136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
9.67Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LGHT Summary
The Langar Global HealthTech ETF (LGHT) is a fund that invests in companies using technology to improve healthcare, rather than tracking a traditional index. It focuses on health care technology, including digital health tools, telemedicine, biotech, and medical devices. Well-known holdings include Moderna and Intuitive Surgical, which are involved in vaccines and robotic surgery. Someone might invest in LGHT for long-term growth and to diversify into innovative healthcare companies. However, this ETF is heavily focused on health tech, so its price can be more volatile and may rise or fall sharply with changes in the healthcare and technology sectors.
How much will it cost me?The Langar Global HealthTech ETF (LGHT) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized healthcare technology companies rather than tracking a broad index.
What would affect this ETF?The Langar Global HealthTech ETF could benefit from growing demand for innovative healthcare solutions, such as telemedicine and advanced medical devices, driven by aging populations and technological advancements. However, it may face challenges from regulatory changes in healthcare, fluctuating global economic conditions, and potential competition within the health tech sector. Its global exposure and focus on leading companies like Intuitive Surgical and Siemens Healthineers position it well for long-term growth but also make it sensitive to international market volatility.
LGHT Top 10 Holdings
LGHT is a pure play on global health-tech, with most of its firepower in a handful of high-profile names. Surgical robotics leader Intuitive Surgical and sleep-apnea specialist ResMed have been losing steam lately, acting as a drag on returns, while IQVIA and Veeva are steadier, helping to balance the picture with rising momentum in data and software-driven healthcare. Moderna and Dexcom add a more volatile edge, with Moderna’s rebound and Dexcom’s steady climb giving the fund some upside spark. Overall, it’s a concentrated bet on innovative medical technology across the U.S. and Europe.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Resmed | 9.65% | $202.96K | $32.38B | -22.98% | 76 Outperform | |
| Intuitive Surgical | 9.11% | $191.65K | $139.37B | -18.90% | 78 Outperform | |
| Veeva Systems | 9.03% | $189.96K | $39.60B | -15.51% | 66 Neutral | |
| IQVIA Holdings | 8.46% | $178.04K | $38.95B | 25.29% | 73 Outperform | |
| GE Healthcare Technologies Inc | 7.68% | $161.53K | $33.28B | -1.09% | 78 Outperform | |
| Moderna | 7.07% | $148.77K | $25.28B | 129.48% | 59 Neutral | |
| Dexcom | 6.45% | $135.63K | $33.87B | 9.82% | 79 Outperform | |
| Koninklijke Philips | 5.57% | $117.18K | $26.63B | -2.30% | 50 Neutral | |
| Siemens Healthineers AG Unsponsored ADR | 5.22% | $109.88K | $50.79B | -17.97% | 74 Outperform | |
| Sonova Holding AG | 4.37% | $91.96K | $17.07B | 4.85% | 68 Neutral |
LGHT Technical Analysis
Positive
―
Price Trends
8.64
Positive
8.53
Positive
9.19
Positive
Market Momentum
0.19
Negative
61.49
Neutral
73.43
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LGHT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 8.85, equal to the 50-day MA of 8.64, and equal to the 200-day MA of 9.19, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 61.49 is Neutral, neither overbought nor oversold. The STOCH value of 73.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LGHT.
LGHT Peer Comparison
Comparison Results
Performance Comparison
LGHT
Langar Global HealthTech ETF
9.20
-1.27
-12.13%
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
GDOC
Goldman Sachs Future Health Care Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents